TAOX (TAO Synergies) Debt-to-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is TAO Synergies Debt-to-Asset?

TAO Synergies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil. TAO Synergies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil. TAO Synergies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was $15.33 Mil. TAO Synergies's debt to asset for the quarter that ended in Mar. 2025 was 0.00.

TAO Synergies Debt-to-Asset Historical Data

The historical data trend for TAO Synergies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TAO Synergies Debt-to-Asset Chart

TAO Synergies Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

TAO Synergies Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of TAO Synergies's Debt-to-Asset

For the Software - Infrastructure subindustry, TAO Synergies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TAO Synergies's Debt-to-Asset Distribution in the Software Industry

For the Software industry and Technology sector, TAO Synergies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where TAO Synergies's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

TAO Synergies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

TAO Synergies's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	17.734
	=	0.00

TAO Synergies's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	15.329
	=	0.00

TAO Synergies (NAS:TAOX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

TAO Synergies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of TAO Synergies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

TAO Synergies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » TAO Synergies Inc (NAS:TAOX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.synaptogen.com

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Executives

Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer	director	C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon	director, officer: Chief Scientific Officer	C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman	director, officer: Chief Executive Officer	18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry	director	C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010